RxDoctor Payments Data

April Brannum

Nurse Practitioner · Bonne Terre, MONPI 1972159341

Payments from drug & device makers

$7,213in general payments, 2019–2025

Across 399 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$593
  • Novo Nordisk$491
  • Neurocrine Biosciences, Inc.$389
  • Boehringer Ingelheim$367
  • GSK$357
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$7,13299%
  • Education$811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,213 in reported general payments places this provider in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$20,218
Medicare patients
152
Services billed
800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$61,397
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$52,795
FarxigaDapagliflozin Propanediol39$33,415
MounjaroTirzepatide30$31,141
TrulicityDulaglutide25$29,060
EliquisApixaban24$23,528
JardianceEmpagliflozin19$15,309
XareltoRivaroxaban15$13,622
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,634
MyrbetriqMirabegron17$8,631
GemtesaVibegron14$8,424
Combivent RespimatIpratropium/Albuterol Sulfate12$5,775
VascepaIcosapent Ethyl13$4,560
Albuterol Sulfate HfaAlbuterol Sulfate143$3,580
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$2,076

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$491$61,39742 claims
Lilly USA, LLCMounjaro, Trulicity$593$60,20155 claims
GSKTrelegy Ellipta$357$52,79556 claims
AstraZenecaFarxiga, Breztri Aerosphere$135$43,04854 claims
PfizerEliquis$153$23,52824 claims
Boehringer IngelheimJardiance, Combivent Respimat$367$21,08331 claims
Johnson & JohnsonXarelto$116$13,62215 claims
Astellas Pharma US IncMyrbetriq$28$8,63117 claims
Sumitomo Pharma America, Inc.Gemtesa$169$8,42414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Bonne Terre

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →